Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Nizatidine
|
| gptkbp:activities |
H2 receptor antagonist
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
generic version available
|
| gptkbp:brand |
Axid
|
| gptkbp:category |
B
|
| gptkbp:class |
H2 antagonist
|
| gptkbp:clinical_trial |
Phase IV
short-term treatment long-term management |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to famotidine |
| gptkbp:current_use |
peptic ulcer disease
Zollinger-Ellison syndrome |
| gptkbp:dosage_form |
suspension
10 mg |
| gptkbp:duration |
as needed
|
| gptkbp:education |
do not exceed recommended dose
take before meals report any unusual symptoms |
| gptkbp:effective_date |
gptkb:1995
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Axid AR
|
| gptkbp:indication |
gastroesophageal reflux disease (GERD)
|
| gptkbp:ingredients |
gptkb:famotidine
C8 H10 N4 O2 S |
| gptkbp:interacts_with |
gptkb:ketoconazole
gptkb:warfarin antacids may increase effects of other drugs |
| gptkbp:is_available_on |
gptkb:drug
|
| gptkbp:is_monitored_by |
renal function
liver function |
| gptkbp:is_used_for |
treatment of heartburn
|
| gptkbp:lifespan |
2.5 to 3.5 hours
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:packaging |
blister pack
|
| gptkbp:population |
adults
elderly |
| gptkbp:rounds |
renal
|
| gptkbp:safety_features |
not recommended for children under 12
|
| gptkbp:scholarships |
consult healthcare provider before use
|
| gptkbp:side_effect |
dizziness
fatigue headache nausea vomiting diarrhea rash constipation minimal risk excreted in breast milk |
| gptkbp:storage |
room temperature
|
| gptkbp:weight |
198.25 g/mol
|